The weekly litigation news digest is live. Subscribe now

IP Verse

Methods For Preventing Cardiovascular Events Through Proprotein Convertase Subtilisin Kexin 9 (Pcsk9) Protein Reduction - EP3529360

The patent EP3529360 was granted to Novartis on Apr 17, 2024. The application was filed on Oct 18, 2017 under application number EP17800976A. The patent is currently recorded with a legal status of "Granted And Under Opposition".

EP3529360

NOVARTIS
Application Number
EP17800976A
Filing Date
Oct 18, 2017
Status
Granted And Under Opposition
Mar 15, 2024
Publication Date
Apr 17, 2024
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions (5)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status
GRAF VON STOSCH PATENTANWALTSGESELLSCHAFTJan 17, 2025LEPTHIENADMISSIBLE
TEVA PHARMACEUTICALSJan 17, 2025VON KAUFFMANNADMISSIBLE
INTAS PHARMACEUTICALSJan 16, 2025BRAND MURRAY FULLERADMISSIBLE
POLPHARMAJan 15, 2025WICHMANNADMISSIBLE
SYNTHONJan 10, 2025REDDIE & GROSEADMISSIBLE

Patent Citations (5) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication Number
DESCRIPTIONWO2016US48666
INTERNATIONAL-SEARCH-REPORTWO2014089313
OPPOSITIONWO2014089313
OPPOSITIONWO2017035340
OPPOSITIONWO2018075658

Dossier Documents

The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents